دورية أكاديمية
أعرض في EDS

Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis.

التفاصيل البيبلوغرافية
العنوان: Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis.
المؤلفون: Yang JW; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Zou Y; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Chen J; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Cui C; Department of Endocrinology, The Second Hospital of Shandong University, Jinan, China., Song J; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Yang MM; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Gao J; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Hu HQ; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Xia LQ; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Wang LM; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Lv XY; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China., Chen L; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.; Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, China.; Jinan Clinical Research Center for Endocrine and Metabolic Disease, Jinan, China.; Institute of Endocrine and Metabolic Diseases, Shandong University, Jinan, China.; National Key Laboratory for Innovation and Transformation of Luobing Theory, Jinan, China.; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China., Hou XG; Department of Endocrinology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China. houxinguo@sdu.edu.cn.; Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province Medicine & Health, Jinan, China. houxinguo@sdu.edu.cn.; Jinan Clinical Research Center for Endocrine and Metabolic Disease, Jinan, China. houxinguo@sdu.edu.cn.; Institute of Endocrine and Metabolic Diseases, Shandong University, Jinan, China. houxinguo@sdu.edu.cn.; National Key Laboratory for Innovation and Transformation of Luobing Theory, Jinan, China. houxinguo@sdu.edu.cn.; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China. houxinguo@sdu.edu.cn.
المصدر: Journal of translational medicine [J Transl Med] 2023 Dec 19; Vol. 21 (1), pp. 921. Date of Electronic Publication: 2023 Dec 19.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, 2003-
مواضيع طبية MeSH: Sirtuin 1*/metabolism , Non-alcoholic Fatty Liver Disease*/metabolism, Animals ; Mice ; Organelle Biogenesis ; Molecular Docking Simulation ; Flavonoids/pharmacology ; Flavonoids/therapeutic use ; Glycosides/pharmacology ; Liver/metabolism
مستخلص: Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the most prevalent metabolic syndromes worldwide. However, no approved pharmacological treatments are available for MAFLD. Chenpi, one kind of dried peel of citrus fruits, has traditionally been utilized as a medicinal herb for liver diseases. Didymin is a newly identified oral bioactive dietary flavonoid glycoside derived from Chenpi. In this study, we investigated the therapeutic potential of Didymin as an anti-MAFLD drug and elucidated its underlying mechanisms.
Methods: High-fat diet (HFD)-induced MAFLD mice and alpha mouse liver 12 (AML12) cells were utilized to evaluate the effects and mechanisms of Didymin in the treatment of MAFLD. Liver weight, serum biochemical parameters, and liver morphology were examined to demonstrate the therapeutic efficacy of Didymin in MAFLD treatment. RNA-seq analysis was performed to identify potential pathways that could be affected by Didymin. The impact of Didymin on Sirt1 was corroborated through western blot, molecular docking analysis, microscale thermophoresis (MST), and deacetylase activity assay. Then, a Sirt1 inhibitor (EX-527) was utilized to confirm that Didymin alleviates MAFLD via Sirt1. Western blot and additional assays were used to investigate the underlying mechanisms.
Results: Our results suggested that Didymin may possess therapeutic potential against MAFLD in vitro and in vivo. By promoting Sirt1 expression as well as directly binding to and activating Sirt1, Didymin triggers downstream pathways that enhance mitochondrial biogenesis and function while reducing apoptosis and enhancing lipophagy.
Conclusions: These suggest that Didymin could be a promising medication for MAFLD treatment. Furthermore, its therapeutic effects are mediated by Sirt1.
(© 2023. The Author(s).)
References: Autophagy. 2023 Feb;19(2):379-387. (PMID: 35435793)
Chem Biol Interact. 2007 Jan 30;165(2):106-16. (PMID: 17188672)
Obesity (Silver Spring). 2014 Oct;22(10):2147-55. (PMID: 24942674)
Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52. (PMID: 17717517)
Molecules. 2018 Oct 06;23(10):. (PMID: 30301216)
Nat Med. 2018 Jul;24(7):908-922. (PMID: 29967350)
Pharmacol Res. 2021 Jul;169:105613. (PMID: 33915297)
Cell Metab. 2009 Apr;9(4):327-38. (PMID: 19356714)
Cell Metab. 2016 Jan 12;23(1):113-27. (PMID: 26698918)
Arq Bras Endocrinol Metabol. 2013 Jul;57(5):339-45. (PMID: 23896799)
Mol Aspects Med. 2021 Dec;82:100973. (PMID: 34120768)
Nat Commun. 2015 Jul 02;6:7645. (PMID: 26134520)
Physiol Rev. 2012 Jul;92(3):1479-514. (PMID: 22811431)
Brain Res. 2003 Nov 28;992(1):9-19. (PMID: 14604768)
Int J Mol Sci. 2021 Feb 26;22(5):. (PMID: 33652942)
Biomed Pharmacother. 2021 Oct;142:112041. (PMID: 34411916)
Neuroendocrinology. 1998 Jan;67(1):29-36. (PMID: 9485166)
J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):429-444. (PMID: 30793539)
Science. 2004 Mar 26;303(5666):2011-5. (PMID: 14976264)
Physiol Behav. 2003 Apr;78(4-5):543-55. (PMID: 12782207)
Cell Signal. 2022 Nov;99:110442. (PMID: 35988807)
Phytomedicine. 2021 Jan;81:153412. (PMID: 33234364)
Lung Cancer. 2010 Jun;68(3):366-74. (PMID: 19733932)
Exp Mol Med. 2019 Apr 26;51(4):1-16. (PMID: 31028246)
Int Immunopharmacol. 2017 Jan;42:130-138. (PMID: 27912149)
Med Res Rev. 2019 Jan;39(1):328-348. (PMID: 29846945)
Gastroenterology. 2020 May;158(7):1999-2014.e1. (PMID: 32044314)
Dev Cell. 2009 May;16(5):628-30. (PMID: 19460339)
Life Sci. 2018 Jun 15;203:291-304. (PMID: 29709653)
Biochem Pharmacol. 2018 Jun;152:1-10. (PMID: 29548811)
Clin Nutr. 2002 Jun;21(3):219-23. (PMID: 12127930)
Cell. 1999 Jul 9;98(1):115-24. (PMID: 10412986)
Signal Transduct Target Ther. 2023 Jan 16;8(1):32. (PMID: 36646695)
Free Radic Biol Med. 2004 Nov 1;37(9):1499-507. (PMID: 15454290)
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9793-8. (PMID: 18599449)
Clin Gastroenterol Hepatol. 2023 Mar;21(3):619-629.e7. (PMID: 34871813)
J Biol Chem. 2012 Nov 9;287(46):39107-14. (PMID: 22992773)
Essays Biochem. 2010;47:69-84. (PMID: 20533901)
PLoS One. 2012;7(5):e37794. (PMID: 22662224)
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3374-9. (PMID: 18296641)
Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):943-953. (PMID: 29990551)
Pharmacol Res. 2021 Oct;172:105849. (PMID: 34450307)
Nutrients. 2017 Sep 27;9(10):. (PMID: 28953222)
Food Sci Nutr. 2016 Oct 02;5(3):545-553. (PMID: 28572940)
J Cardiovasc Pharmacol. 2020 Jul;76(1):86-93. (PMID: 32324654)
Metabolism. 2016 Aug;65(8):1038-48. (PMID: 26823198)
Dev Cell. 2011 Jan 18;20(1):131-9. (PMID: 21238931)
Am J Pathol. 2013 Dec;183(6):1815-1825. (PMID: 24095927)
Biomed Pharmacother. 2017 Jul;91:621-631. (PMID: 28486193)
J Endocrinol Invest. 2020 Apr;43(4):493-503. (PMID: 31705397)
Aging (Albany NY). 2020 Jul 3;12(13):13187-13205. (PMID: 32620714)
Chem Biol Interact. 2019 May 25;305:180-194. (PMID: 30928401)
Trends Endocrinol Metab. 2014 Mar;25(3):138-45. (PMID: 24388149)
Nutrients. 2016 Dec 11;8(12):. (PMID: 27973423)
Oncotarget. 2017 Apr 25;8(17):29428-29441. (PMID: 28187004)
Nutrients. 2019 Dec 16;11(12):. (PMID: 31888190)
Int Immunopharmacol. 2020 Nov;88:107003. (PMID: 33182043)
J Gastroenterol Hepatol. 2009 May;24(5):830-40. (PMID: 19207680)
Hepatol Res. 2016 Aug;46(9):933-43. (PMID: 26666995)
Autophagy. 2007 Sep-Oct;3(5):452-60. (PMID: 17534139)
Oxid Med Cell Longev. 2018 Feb 20;2018:3159801. (PMID: 29675132)
Biomed Pharmacother. 2019 Oct;118:109227. (PMID: 31351433)
Trends Endocrinol Metab. 2019 Dec;30(12):903-914. (PMID: 31597607)
Autophagy. 2017 Jul 3;13(7):1130-1144. (PMID: 28548876)
Science. 2004 Dec 17;306(5704):2105-8. (PMID: 15604409)
Front Physiol. 2020 Jul 17;11:850. (PMID: 32765301)
Int J Mol Sci. 2020 Jan 06;21(1):. (PMID: 31935815)
Eur J Pharmacol. 2021 May 5;898:173976. (PMID: 33639194)
Crit Rev Food Sci Nutr. 2020;60(4):566-583. (PMID: 30580548)
Hepatology. 2019 Feb;69(2):545-563. (PMID: 30102772)
Molecules. 2010 Aug 05;15(8):5378-88. (PMID: 20714303)
Nat Cell Biol. 2015 Jun;17(6):759-70. (PMID: 25961502)
Aging Cell. 2007 Dec;6(6):759-67. (PMID: 17877786)
Obesity (Silver Spring). 2010 Mar;18(3):463-9. (PMID: 19730425)
Food Funct. 2021 May 11;12(9):3898-3918. (PMID: 33977953)
Nature. 2005 Mar 3;434(7029):113-8. (PMID: 15744310)
Cell Physiol Biochem. 2016;40(6):1422-1432. (PMID: 27997902)
J Ethnopharmacol. 2020 Apr 6;251:112442. (PMID: 31891799)
Biomolecules. 2022 Jun 13;12(6):. (PMID: 35740949)
Clin Sci (Lond). 2022 Sep 30;136(18):1347-1366. (PMID: 36148775)
Drug Des Devel Ther. 2022 Jun 07;16:1713-1729. (PMID: 35698653)
Int J Pharm. 2007 Aug 16;341(1-2):1-19. (PMID: 17658228)
Biochem Biophys Res Commun. 2017 Feb 5;483(2):885-891. (PMID: 28077277)
Phytomedicine. 2019 Jun;59:152782. (PMID: 31005808)
Autophagy. 2022 Jan;18(1):50-72. (PMID: 33794741)
Int J Biol Sci. 2022 Sep 6;18(15):5681-5697. (PMID: 36263163)
Oncol Lett. 2016 Feb;11(2):1035-1042. (PMID: 26893687)
J Sci Food Agric. 2016 Jan 15;96(1):73-8. (PMID: 25546309)
Cells Tissues Organs. 2014;199(2-3):184-200. (PMID: 25412833)
Biochem Biophys Res Commun. 2022 Jul 5;612:169-175. (PMID: 35533489)
Gastroenterology. 2018 Sep;155(3):629-647. (PMID: 30012333)
Autophagy. 2022 Apr;18(4):860-876. (PMID: 34382907)
Front Nutr. 2022 Oct 18;9:1033129. (PMID: 36330148)
Mediators Inflamm. 2023 Jan 12;2023:6051946. (PMID: 36687218)
Autophagy. 2015;11(1):46-59. (PMID: 25484077)
Mech Ageing Dev. 2016 Apr;155:10-21. (PMID: 26923269)
J Clin Endocrinol Metab. 2022 Feb 17;107(3):788-800. (PMID: 34665857)
Oncotarget. 2016 Nov 22;7(47):76508-76522. (PMID: 27793014)
Hepatology. 2003 Apr;37(4):909-16. (PMID: 12668986)
معلومات مُعتمدة: 82270845 National Natural Science Foundation of China; 26010162914001 Double First Class University Plan; ZR2020ZD15 Natural Science Foundation of Shandong Province
فهرسة مساهمة: Keywords: Apoptosis; Didymin; FoxO3a; Lipophagy; MAFLD; Mitochondrial function; PGC-1α; Sirt1
المشرفين على المادة: 0 (didymin)
EC 3.5.1.- (Sirtuin 1)
0 (Flavonoids)
0 (Glycosides)
EC 3.5.1.- (Sirt1 protein, mouse)
تواريخ الأحداث: Date Created: 20231220 Date Completed: 20231221 Latest Revision: 20240626
رمز التحديث: 20240626
مُعرف محوري في PubMed: PMC10731721
DOI: 10.1186/s12967-023-04790-4
PMID: 38115075
قاعدة البيانات: MEDLINE
الوصف
تدمد:1479-5876
DOI:10.1186/s12967-023-04790-4